Harvard Bioscience (HBIO) Price to FCF (2010 - 2026)

Harvard Bioscience (HBIO) has reported Price to FCF for 17 consecutive years, with 77.13 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Price to FCF fell 1149.4% year-over-year to 77.13 in Q2 2026; TTM through Jun 2026 was 25.02, a 718.15% decrease from a year earlier, with the FY2025 full-year figure at 5.48, up 107.09% from the prior year.
• Price to FCF was 77.13 for Q2 2026 at Harvard Bioscience, down from 20.19 in the prior quarter.
• Over five years, Price to FCF peaked at 515.19 in Q3 2022 and troughed at 236.39 in Q2 2022.
• A 5-year average of 31.95 and a median of 16.28 in 2025 frame the typical range for Price to FCF.
• Across the five-year window, Price to FCF jumped 306.19% in 2022 and tumbled 1149.4% in 2026, its largest moves.
• Over 5 years, Price to FCF stood at 47.69 in 2022, then soared by 40.16% to 66.85 in 2023, then dropped by 2.3% to 65.31 in 2024, then plunged by 184.18% to 54.98 in 2025, then sank by 40.29% to 77.13 in 2026.
• The last three Price to FCF figures came in at 77.13 (Q2 2026), 20.19 (Q1 2026), and 54.98 (Q4 2025), per Business Quant data.